The partners will adapt Eukarÿs' C3P3 engineered enzyme tech to work with adeno-associated virus vectors to boost biomanufacturing yields.

Viralgen and Axovia Therapeutics are set to form a partnership to progress the development and manufacturing of an ...

Genethon & Eukarÿs enter strategic partnership to develop a breakthrough technology to reduce the biomanufacturing cost of gene therapies: Evry, France Friday, January 24, 2025, ...

The goal is to treat familial dysautonomia patients with a single injection.

Additional details on the meeting can be found at the WORLD Symposium website. About Spur Therapeutics Spur Therapeutics is a clinical-stage biotechnology company focused on developing life-changing ...

Axovia’s lead program AXV101 is an adeno-associated virus (AAV9)-based investigational gene therapy that aims to slow down or ...

New Vericheck ddPCR Empty-Full Capsid Kits for AAV Serotypes 2 and 8 Provide Precise Measurement of Viral Titer and Capsid ...

Explore the role of preclinical MRI in studying neurological diseases, with a focus on advanced cellular and molecular ...

As translational CRISPR-based research continues to make waves in laboratories and the clinic, scientists across life science disciplines pursue out-of-the-ordinary genome editing applications. From ...

Partnership complements Sapient’s mass spectrometry-based proteomics services, extends multi-omics solutions, and will enable development of NULISAseq™ assays under regulated guidance Explore how the ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...